Interferons  ||| S:0 E:12 ||| JJ
beta  ||| S:12 E:17 ||| NNS
have  ||| S:17 E:22 ||| VBP
vasoconstrictive  ||| S:22 E:39 ||| VBN
and  ||| S:39 E:43 ||| CC
procoagulant  ||| S:43 E:56 ||| JJ
effects ||| S:56 E:63 ||| NNS
:  ||| S:63 E:65 ||| :
a  ||| S:65 E:67 ||| DT
woman  ||| S:67 E:73 ||| NN
who  ||| S:73 E:77 ||| WP
developed  ||| S:77 E:87 ||| VBD
livedo  ||| S:87 E:94 ||| JJ
reticularis  ||| S:94 E:106 ||| NN
and  ||| S:106 E:110 ||| CC
Raynaud  ||| S:110 E:118 ||| NNP
phenomenon  ||| S:118 E:129 ||| NN
in  ||| S:129 E:132 ||| IN
association  ||| S:132 E:144 ||| NN
with  ||| S:144 E:149 ||| IN
interferon  ||| S:149 E:160 ||| JJ
beta  ||| S:160 E:165 ||| NN
treatment  ||| S:165 E:175 ||| NN
for  ||| S:175 E:179 ||| IN
multiple  ||| S:179 E:188 ||| JJ
sclerosis  ||| S:188 E:198 ||| NNS
A  ||| S:198 E:200 ||| DT
31-year-old  ||| S:200 E:212 ||| JJ
woman  ||| S:212 E:218 ||| NN
with  ||| S:218 E:223 ||| IN
MS  ||| S:223 E:226 ||| NNP
developed  ||| S:226 E:236 ||| VBD
livedo  ||| S:236 E:243 ||| JJ
reticularis  ||| S:243 E:255 ||| NN
and  ||| S:255 E:259 ||| CC
secondary  ||| S:259 E:269 ||| JJ
Raynaud  ||| S:269 E:277 ||| JJ
phenomenon  ||| S:277 E:288 ||| NN
2.5  ||| S:288 E:292 ||| CD
years  ||| S:292 E:298 ||| NNS
after  ||| S:298 E:304 ||| IN
introduction  ||| S:304 E:317 ||| NN
of  ||| S:317 E:320 ||| IN
interferon  ||| S:320 E:331 ||| CD
beta-1b ||| S:331 E:338 ||| CD
.  ||| S:338 E:340 ||| .
The  ||| S:340 E:344 ||| DT
symptoms  ||| S:344 E:353 ||| NNS
disappeared  ||| S:353 E:365 ||| VBD
after  ||| S:365 E:371 ||| IN
withdrawal  ||| S:371 E:382 ||| NN
of  ||| S:382 E:385 ||| IN
the  ||| S:385 E:389 ||| DT
drug ||| S:389 E:393 ||| NN
.  ||| S:393 E:395 ||| .
Livedo  ||| S:395 E:402 ||| JJ
reticularis  ||| S:402 E:414 ||| NN
and  ||| S:414 E:418 ||| CC
Raynaud  ||| S:418 E:426 ||| NNP
phenomenon  ||| S:426 E:437 ||| NN
as  ||| S:437 E:440 ||| IN
well  ||| S:440 E:445 ||| RB
as  ||| S:445 E:448 ||| IN
pulmonary  ||| S:448 E:458 ||| JJ
arterial  ||| S:458 E:467 ||| JJ
hypertension ||| S:467 E:479 ||| NN
,  ||| S:479 E:481 ||| ,
venous  ||| S:481 E:488 ||| FW
sinus  ||| S:488 E:494 ||| FW
thrombosis ||| S:494 E:504 ||| FW
,  ||| S:504 E:506 ||| ,
pulmonary  ||| S:506 E:516 ||| JJ
embolism  ||| S:516 E:525 ||| NN
and  ||| S:525 E:529 ||| CC
renal  ||| S:529 E:535 ||| JJ
thrombotic  ||| S:535 E:546 ||| JJ
microangiopathy  ||| S:546 E:562 ||| NNS
have  ||| S:562 E:567 ||| VBP
all  ||| S:567 E:571 ||| RB
been  ||| S:571 E:576 ||| VBN
described  ||| S:576 E:586 ||| VBN
in  ||| S:586 E:589 ||| IN
association  ||| S:589 E:601 ||| NN
with  ||| S:601 E:606 ||| IN
interferon  ||| S:606 E:617 ||| JJ
beta  ||| S:617 E:622 ||| NN
therapy ||| S:622 E:629 ||| NN
.  ||| S:629 E:631 ||| .
These  ||| S:631 E:637 ||| DT
complications  ||| S:637 E:651 ||| NNS
strongly  ||| S:651 E:660 ||| RB
suggest  ||| S:660 E:668 ||| VB
that  ||| S:668 E:673 ||| DT
type  ||| S:673 E:678 ||| NN
I  ||| S:678 E:680 ||| PRP
interferons  ||| S:680 E:692 ||| RB
have  ||| S:692 E:697 ||| VB
vasoconstrictive  ||| S:697 E:714 ||| NNS
and  ||| S:714 E:718 ||| CC
procoagulant  ||| S:718 E:731 ||| JJ
effects  ||| S:731 E:739 ||| NNS
with  ||| S:739 E:744 ||| IN
potentially  ||| S:744 E:756 ||| RB
serious  ||| S:756 E:764 ||| JJ
systemic  ||| S:764 E:773 ||| JJ
complications ||| S:773 E:786 ||| NNS
.  ||| S:786 E:788 ||| .
